<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322292</url>
  </required_header>
  <id_info>
    <org_study_id>QT-2019007-EC-2</org_study_id>
    <nct_id>NCT04322292</nct_id>
  </id_info>
  <brief_title>A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma</brief_title>
  <official_title>A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, non-randomized and dose-escalation study to evaluate the safety and
      efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include the following sequential phases: Screening, Pre- Treatment (Cell
      Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: The incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>30 days</time_frame>
    <description>The incidence of treatment-emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>ORR(including sCR / CR / VGPR / PR, based on IMWG 2016 efficacy evaluation criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 months、12 months</time_frame>
    <description>PFS(based on IMWG 2016 efficacy evaluation criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The CART cell duration in vivo</measure>
    <time_frame>12 months</time_frame>
    <description>The copys of BCMA-CART DNA in peripheral blood with qPCR method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The soluble BCMA changes in peripheral blood</measure>
    <time_frame>12 months</time_frame>
    <description>The amount of soluble BCMA in peripheral blood with ELISA method</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>C-CAR088</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C-CAR088</intervention_name>
    <description>Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10^6 anti-BCMA CAR+T cells/kg.
Divided into three dose ranges of low(1.0-3.0×10^6 CAR+T cells/kg),medium(3.0-6.0×10^6 CAR+T cells/kg) and high(6.0-9.0×10^6 CAR+T cells/kg).
Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.</description>
    <arm_group_label>C-CAR088</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75 years old, male or female;

          2. The patient volunteered to participate in the study, and he or his legal guardian
             signed the Informed Consent;

          3. Meet the internationally accepted Criteria for the diagnosis of multiple myeloma (IMWG
             diagnostic criteria 2014);

          4. Patients with a clear diagnosis of relapsed or refractory multiple myeloma who have
             received at least 3 lines of MM (Contains proteasome inhibitors and immunomodulatory
             therapies that progress or relapse during the most recent treatment or after the end
             of treatment). Note: The planned treatment plan for one or more cycles is &quot;one-line
             treatment&quot;; induction chemotherapy, stem cell transplantation, and maintenance
             treatment (if there is no disease progression between them), it is considered as a
             one-line treatment plan;

          5. The patient have one or more measurable multiple myeloma lesion, must include one of
             the following conditions:

               -  Serum M protein≥1.0 g/dL(10g/L)

               -  Urine M protein≥200 mg/24h

               -  Serum free light chain(sFLC): κ/λ FLC ratio is abnormal and affected FLC ≥10mg /
                  dL

          6. Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological
             examination;

          7. ECOG scores 0 - 1;

          8. Echocardiography showed normal diastolic function, left ventricular ejection fraction
             (LVEF) ≥50%, and no severe arrhythmia;

          9. No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92%
             on room air.

         10. Absolute neutrophil count ≥1.0 × 109 / L, platelet count ≥50 × 109 / L; total serum
             bilirubin ≤1.5mg / dl; serum ALT or AST less than 2.5 times the upper limit of normal;
             serum creatinine ≤2.0mg / dl;

         11. No contraindications of peripheral blood apheresis;

         12. Expected survival time &gt; 12 weeks;.

         13. Female subjects of childbearing age must have a negative urine / blood pregnancy test
             within 7 days before cell therapy and not be in lactation; female or male subjects of
             childbearing age need to take effective contraception throughout the study.

        Exclusion Criteria:

          1. Have a history of allergy to cell ular products;

          2. Presence of clinically significant cardiovascular disease, such as uncontrolled or
             symptomatic arrhythmias, congestive heart failure, or any heart function Grade 3
             (moderate) or Grade 4 (severe) heart disease (according to the New York Heart
             Association Function Classification method: NYHA); patients with a history of
             myocardial infarction, cardiac angioplasty or stent implantation, unstable angina
             pectoris or other clinically significant heart disease within 12 months before
             enrollment;

          3. A history of craniocerebral trauma, consciousness disorder, epilepsy, severe cerebral
             ischemia or hemorrhagic disease;

          4. Need to use any anticoagulant (except aspirin);

          5. Patients requiring urgent treatment due to tumor progression or spinal cord
             compression;

          6. Patients with CNS metastasis or symptoms of CNS involvement;

          7. After allogeneic hematopoietic stem cell transplantation;

          8. Plasma cell leukemia;

          9. Received systemic anti-tumor treatment within 2 weeks before apheresis, and within 1
             week before apheresis, prednisone (or equivalent amount of other corticosteroids) was
             applied in excess of 5 mg/d ;

         10. Patients with autoimmune diseases, immunodeficiency, or other immunosuppressive
             agents;

         11. Uncontrolled active infection;

         12. Have used any CAR T cell products or other genetically modified T cell therapy before;

         13. Live vaccination within 4 weeks before enrollment;

         14. Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as
             acquired, congenital immune deficiency diseases, including but not limited to HIV
             infected persons;

         15. Have a history of alcoholism, drug addiction and mental illness;

         16. Participated in any other clinical trial within 1 months;

         17. The investigators believe that there are other circumstances that are not suitable for
             the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gang An, PhD&amp;MD</last_name>
    <phone>008613502181109</phone>
    <email>angang@ihcams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>InstituteHBDH</name>
      <address>
        <city>TianJin</city>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang An, PhD&amp;MD</last_name>
      <phone>+008613502181109</phone>
      <email>angang@ihcams.ac.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>AnGang</investigator_full_name>
    <investigator_title>Deputy Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

